Company intelligence / Profile preview

Omega Pharma

Nazareth, East Flanders, Belgium

Ownership: Private
Development stage: Other

Overview

Omega Pharma was a leading European pharmaceutical company specializing in over-the-counter (OTC) medicines and consumer healthcare products. It was acquired by Perrigo in 2015 for $4.76 billion. Its best-known brands cover dermatology, nutritional supplements, weight management, and cough/cold relief. The company had a diverse, primarily commercialized pipeline with no new chemical entities in clinical development.

Therapeutic areas: OtherEndocrinologyNeurologyDermatologyInfectious DiseasesPulmonologyGastroenterologyMetabolic DisordersOphthalmology
Modalities: Small moleculeNutraceuticalMedical device
Industry: Biotech

Partnerships

Dompé Farmaceutici (distribution)Kwizda Pharma (co-marketing)NovaMedica (co-marketing)Sienna Biotec (co-development)Hikma Pharmaceuticals (licensing)BioLineRx (licensing for BL-5010)

Beyond the preview

Go deeper on Omega Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omega Pharma.

Explore the full profile